Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.88 | — | — | — | — | 4.94 | — | — | — | — | — | 3.67 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.59 | 88.16 | 1.90 | 5.61 | 7.10 | 0.94 | 51.32 | 62.82 | 11.81 | 2.83 | 8.29 | 0.47 | 4.75 |
| — | +9287.4% | -96.3% | -91.1% | -39.9% | -66.8% | +519.1% | +13230.0% | +148.8% | -61.4% | +58.8% | -93.7% | -51.4% | |
| P/B Ratio | 3.83 | 32.82 | 7.10 | 29.44 | 9.42 | 4.74 | 3.08 | 2.13 | 1.16 | 0.79 | 0.97 | 0.89 | 1.75 |
| — | +591.9% | +130.0% | +1281.2% | +708.7% | +502.2% | +218.0% | +140.3% | -33.6% | -68.6% | -49.7% | -65.1% | -39.8% | |
| P/FCF | — | — | — | — | — | 3.99 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | 3.41 | — | — | — | — | — | 2.99 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | 4.10 | — | — | — | — | — | 0.84 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Sangamo Therapeutics, Inc.'s operating margin was -6119.3% in Q3 2025, down 6021.7 pp QoQ and down 6140.8 pp YoY. The trailing four-quarter average of -1755.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -507.5% | -766.8% | 60.0% | -143.0% |
| — | 0.0% | 0.0% | 0.0% | 0.0% | +119.7% | +113.0% | +66.7% | +169.9% | -247.4% | -635.2% | +155.8% | -68.1% | |
| Operating Margin | -179.9% | -6119.3% | -97.5% | -460.3% | -344.2% | 21.5% | -10416.9% | -10712.3% | -3039.1% | -1132.2% | -1807.9% | 11.4% | -203.4% |
| — | -28541.9% | +99.1% | +95.7% | +88.7% | +101.9% | -476.2% | -93927.3% | -1394.0% | -445.8% | -1061.4% | +107.1% | -42.7% | |
| Net Margin | -169.4% | -6012.0% | -109.2% | -475.3% | -309.8% | 21.6% | -10148.3% | -10205.6% | -2952.7% | -1108.4% | -1675.3% | 13.4% | -190.9% |
| — | -27936.1% | +98.9% | +95.3% | +89.5% | +101.9% | -505.8% | -76380.8% | -1447.0% | -451.7% | -1040.0% | +108.6% | -42.5% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -185.4% | -270.3% | -163.1% | -221.1% | -75.6% | 34.0% | -89.9% | -70.3% | -55.4% | -56.5% | -40.2% | 6.7% | -17.2% |
| — | -895.6% | -81.5% | -214.4% | -36.5% | +160.1% | -123.4% | -1149.4% | -221.8% | -233.6% | -204.2% | +154.1% | -79.3% | |
| ROA | -73.4% | -37.5% | -21.8% | -32.6% | -22.0% | 10.4% | -32.6% | -33.4% | -31.3% | -38.2% | -29.9% | 4.2% | -9.0% |
| — | -459.1% | +33.2% | +2.3% | +29.8% | +127.3% | -8.8% | -891.8% | -248.4% | -335.6% | -340.4% | +165.9% | -79.1% | |
| ROIC | -178.8% | -910.4% | -287.3% | -277.4% | -99.8% | 30.3% | -95.7% | -71.0% | -49.2% | -50.4% | -37.2% | 5.1% | -16.9% |
| — | -3106.4% | -200.1% | -290.8% | -102.7% | +160.1% | -157.4% | -1497.8% | -191.3% | -204.0% | -170.7% | +137.5% | -43.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 34.7% YoY to 0.88x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.34 | 4.07 | 1.20 | 5.07 | 1.34 | 0.71 | 1.23 | 0.54 | 0.46 | 0.26 | 0.16 | 0.11 | 0.15 |
| — | +474.8% | -2.6% | +832.9% | +192.0% | +173.3% | +689.0% | +383.9% | +214.5% | +101.8% | +19.3% | -12.2% | +14.1% | |
| Debt / EBITDA | — | — | — | — | — | 2.17 | — | — | — | — | — | 1.75 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.13 | 0.88 | 1.05 | 0.76 | 1.13 | 1.35 | 1.03 | 1.71 | 1.98 | 3.04 | 2.97 | 3.93 | 2.69 |
| — | -34.7% | +1.9% | -55.5% | -42.9% | -55.8% | -65.4% | -56.6% | -26.5% | +10.6% | +3.8% | +36.8% | -13.8% | |
| Quick Ratio | 1.13 | 0.88 | 1.05 | 0.76 | 1.13 | 1.35 | 1.03 | 1.71 | 1.98 | 3.04 | 2.97 | 3.93 | 2.69 |
| — | -34.7% | +1.9% | -55.5% | -42.9% | -55.8% | -65.4% | -56.6% | -26.5% | +10.6% | +3.8% | +36.8% | -13.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonSangamo Therapeutics, Inc.'s current P/E is -0.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Sangamo Therapeutics, Inc.'s current operating margin is -179.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sangamo Therapeutics, Inc.'s business trajectory between earnings reports.